BWH Cancer Research Symposium

Tuesday, December 17, 2024
11:00 a.m. - 4:15 p.m.

The Brigham Research Institute (BRI) cordially invites members of the community to participate in the upcoming BWH Cancer Research Symposium. The event will feature cutting-edge research presentations and an interactive poster session with Brigham and MGB-affiliated researchers. The goal of the symposium is to bring together the community, highlight the breadth and depth of cancer research at BWH and MGB, and foster interdisciplinary research collaborations.

Agenda

The event consists of a series of research presentations and short talks (Plenary Talks) followed by a two-round poster session and award ceremony.

11:00 AM - 2:50 PM | Plenary Talks

* Speakers marked with an asterisk (*) are featured speakers who were chosen from submitted abstracts to orally present short talks on their work.

11:00 AM-11:10 AM | Kickoff and Opening Remarks

11:10 AM-12:00 PM | Cancer Prevention and Early Detection
Moderator: Aditi Hazra, PhD, MPH

12:00-12:25 PM | Patient Well-Being and Survivorship
Moderator: Aditi Hazra, PhD, MPH

  • Desiree Azizoddin, PsyD – Featured Short Talk
    • Feasibility Testing of an mHealth Application (STAMP+CBT) that Integrates Pain-Cognitive Behavioral Therapy (pain-CBT) with Pharmacologic Education to Support Pain Management in Advanced Cancer Patients
  • Hermioni Amonoo, MD, MPP, MPH
    • A Virtual Reality Delivered Psychosocial Intervention (BMT-VR) for Patients Undergoing Hematopoietic Stem Cell Transplantation

12:25 - 12:40 PM | Lunch

12:40-1:30 PM | Diagnosis and Treatment
Moderator: Trey Toombs, PhD

  • Ross Berbeco, PhD
    • Nanoparticles in Radiation Therapy: From Bench to MR-Guided Bedside
  • * Shruti Gupta, MD, MPH
    • F18-FDG PET-CT Imaging: A Novel Diagnostic Tool for Immune Checkpoint Inhibitor-associated AKI
  • Clare Tempany, MB, BCh, BAO
    • Prostate cancer diagnosis and treatment: a report from The National Center of Image Guided Therapy

1:30 - 1:45 PM | Coffee Break

1:45-2:45 PM | Basic/Fundamental Research
Moderator: Ana Anderson, PhD

2:45 PM | Plenary Session Closing Remarks

* Speakers marked with an asterisk (*) are featured speakers who were chosen from submitted abstracts to orally present short talks on their work.

2:50 PM - 4:15 PM | Poster Sessions

2:50-3:20 PM | Poster Session – Round 1

3:30-4:00 PM | Poster Session – Round 2

4:00-4:15 PM | Awards and Closing Remarks

Speakers and Presenters

* Speakers marked with an asterisk (*) are featured speakers who were chosen from submitted abstracts to orally present short talks on their work.

Hermioni Amonoo, MD, MPP, MPH
Associate Professor of Psychiatry

A Virtual Reality Delivered Psychosocial Intervention (BMT-VR) for Patients Undergoing Hematopoietic Stem Cell Transplantation

Hermioni L. Amonoo, MD, MP, MPH is the Carol C. Nadelson, MD Endowed Chair in Psychiatry at the Brigham and Women’s Hospital (BWH). She is a physician-scientist in the Department of Psychosocial Oncology and Palliative Care at the Dana-Farber Cancer Institute (DFCI) and Director of the Wellbeing and Cancer Research Program in the Department of Psychiatry at BWH. She is a graduate of Harvard Medical School (MD), Harvard Kennedy School of Government (MPP), Harvard Chan School of Public Health (MPH), the Massachusetts General Hospital Adult Psychiatry Residency Training Program and the BWH/DFCI Consultation-Liaison Psychiatry/Psychosocial Oncology Fellowship Training Program. Her program of research aims to understand the wellbeing needs of vulnerable cancer populations to develop innovative and practical psychological and digital therapeutics for patients with cancer and their caregivers. Her research has been consistently funded by Harvard Medical School, the Harvard Catalyst, the Brigham and Women’s Hospital/Brigham Research Institute, the National Cancer Institute (NCI), National Institute of Health (NIH), and several foundations.

Ana Anderson, PhD
Albert H. Coons Professor of Neurology

Moderator, Basic/Fundamental Research

Dr. Anderson is the Albert H. Coons Professor of Neurology at Harvard Medical School, Scientist at the Brigham and Women’s Hospital, Institute Member of the Broad Institute of MIT and Harvard, Core Faculty of the Evergrande Center for Immunologic Diseases, and Co-Chair of the Infectious and Immunologic Diseases Program at the Brigham Research Institute. She obtained her B.S. in Microbiology and Immunology in 1993 from the University of Miami, where she graduated summa cum laude. She obtained her Ph.D. in Immunology from Harvard University in 1999. During her Ph.D., she was awarded a fellowship from the Howard Hughes Medical Institute. Dr. Anderson works in the field of cancer immunology, specifically on the regulation of the anti-tumor T cell response. Her laboratory identified that the co-inhibitory molecule Tim-3 is a key regulator of T cell dysfunction in cancer and has identified gene programs associated with activated, dysfunctional, and stem-like CD8+ T cell states in cancer. Prior to working in the field of cancer immunology, Dr. Anderson worked in the field of autoimmunity. Dr. Anderson has published over 60 original papers, 19 reviews, and 5 book chapters and has been recognized as a Highly Cited Researcher in 2020,2021, and 2022 by Clarivate. Her work on T cell cross-reactivity in autoimmunity was selected by Nature Immunology as a ‘Classic Paper in Autoimmunity’ and has also had several papers selected as either ‘must-read’ or ‘recommended’ by the Faculty of 1000. Dr. Anderson is on the editorial board for OncoImmunology and The Journal for Immunotherapy of Cancer. She currently serves on the scientific advisory boards for Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zumutor Biologics, ImmuneOncia, and Excepgen and is a paid consultant for iTeos Therapeutics and Larkspur Biosciences.

* Desiree Azizoddin, PsyD
Assistant Professor of Psychiatry

Feasibility Testing of an mHealth Application (STAMP+CBT) that Integrates Pain-Cognitive Behavioral Therapy (pain-CBT) with Pharmacologic Education to Support Pain Management in Advanced Cancer Patients

Desiree Azizoddin is a behavioral scientist and pain psychologist at the Dana-Farber Cancer Institute, an Assistant Professor at Harvard Medical School, and affiliate faculty at BWH. Her research specializes in developing novel behavioral pain management interventions for patients with cancer who are using opioids. Her projects are currently supported by two NIH, NCI-funded K08 and R21 awards.

Elisabeth Battinelli, MD, PhD
Associate Professor of Medicine, Division of Hematology

Crosstalk between Platelets and Tumor Cells to Support Metastasis

Dr. Elisabeth Battinelli holds an undergraduate degree from Harvard University, a MSc. From Oxford University and an MD/PhD from Boston University School of Medicine. She completed a residency in Internal Medicine at Boston Medical Center and was a Chief Medical Resident. She pursued a Hematology/Oncology Fellowship at Beth Israel Deaconess Medical Center. She is currently an Associate Professor at Brigham and Women’s Hospital/Harvard Medical School. Since joining the Division of Hematology at Brigham and Women’s Hospital, she has focused on both clinical care and research with expertise in thrombosis/hemostasis and platelet disorders. Her clinical responsibilities are centered within the Division of Hematology and the Hemostasis and Thrombosis Clinic with a focus on patients with platelet disorders.

She also is the Clinical Director of the Special Coagulation Laboratory MGB in conjunction with the Pathology Department and Associate Chief of Hematology Research Division. In addition to her clinical responsibilities, Dr. Battinelli also has a research laboratory that focuses on Platelet Biology and is Director of the Translational Hemostasis and Coagulation Research Laboratory. She is interested in understanding the essential role of platelets in malignancy and aims to understand the interaction of platelets and tumor cells. Dr. Battinelli is an active member of the American Society of Hematology and was the Co-Chair for the 2019 Educational Meeting and currently serves as a member of the Committee for Scientific Affairs. In addition, she serves on the Northeastern Board of the American Cancer Society and Co-Chaired the 2020 and 2021 ResearcHERS Campaign. She is also an Associate Editor for Journal of Thrombosis and Hemostasis and serves on the Editorial Boards for Blood Advances and Blood Vessels, Thrombosis and Hemostasis.

Ross Berbeco, PhD
Associate Professor of Radiation Oncology

Nanoparticles in Radiation Therapy: From Bench to MR-Guided Bedside

Dr. Berbeco is the Interim Chief of the Division of Medical Physics and Biophysics at the Brigham and Women's Hospital, Director of Medical Physics Research at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute, and an Associate Professor at Harvard Medical School. Originally trained in High-Energy Physics, Dr. Berbeco received Postdoctoral training at the Massachusetts General Hospital and Harvard Medical School under the supervision of Dr. Steve Jiang. Since 2005, Dr. Berbeco has been a faculty member at the BWH/DFCI, receiving ABR certification in 2010. His research interests include real-time motion management, novel imaging devices, 4DPET/CT, nanoparticles as radiation amplifiers, and pre-clinical radiation therapy. To perform this work, Dr. Berbeco has been a primary mentor for over 30 postdoctoral fellows, graduate and undergraduate students with funding provided by Industrial and Federal sources.

* Antonio Ferreira, PhD
Research Fellow in Pathology

The Human B-Cell Lymphoma Proliferative Microenvironment at Single-Cell Resolution

Antonio Ferreira is originally from Lisbon, Portugal. He completed his PhD in Cell Biology at University College London and he is currently a postdoctoral researcher in the Department of Pathology at Brigham and Women’s Hospital under the mentorship of Dr. Jon Aster. His research focuses on cancer microenvironment in B cell lymphomas, a type of cancer that proliferates in human lymph nodes. In this project, he aims to understand how cell-cell communication contributes to sustaining malignant cancer cell growth, and how we can harness these cell-cell interactions to treat these incurable cancers.

Alexandra Golby, MD, MPH
Professor of Neurosurgery

Dr. Alexandra J. Golby is a Neurosurgeon, Director of Image-guided Neurosurgery, Co-director of the Advanced Multi-modality Image guided OR (AMIGO), and Director of the clinical fMRI service at Brigham and Women’s Hospital in Boston. She is Professor of Neurosurgery and Professor of Radiology at Harvard Medical School. Dr. Golby holds the Haley Distinguished Chair in the Neurosciences at BWH. She is also Principal Investigator of Golby Lab, a surgical brain mapping laboratory. Dr. Golby has special clinical interests in brain surgery for patients with brain tumors and epilepsy, especially those lesions which are intimately associated with critical brain structures. Her translational research is focused on advanced imaging and image guidance to improve care for patients undergoing intracranial neurosurgery. She has developed numerous technologies to help guide presurgical planning and intraoperative decision making. She works closely with scientists across many disciplines including computer science, applied mathematics, MR and ultrasound physics, and biomedical engineering and is very involved with mentoring young clinicians and scientists. Dr. Golby was a recent Fulbright Global Scholar pursuing work to foster interdisciplinary collaborations between technical experts and clinicians in host countries Rwanda and Morocco.

* Shruti Gupta, MD, MPH
Assistant Professor of Medicine, Division of Renal Medicine

F18-FDG PET-CT Imaging: A Novel Diagnostic Tool for Immune Checkpoint Inhibitor-associated AKI

Shruti Gupta MD, MPH is an Assistant Professor of Medicine at Harvard Medical School and Director of Onconephrology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute (DFCI). Dr. Gupta conducts epidemiologic, translational, and interventional studies related to the nephrotoxic effects of cancer therapies. She is funded by an NIH K23 award examining therapeutic targets for cisplatin-associated acute kidney injury (AKI), an R03 award, along with several investigator-initiated industry-funded studies. She is co-principal investigator of an international multicenter study examining outcomes among patients with immune checkpoint inhibitor-associated AKI (ICI-AKI); her first-author publication on clinical features and outcomes of ICI-AKI was selected as Clinical/Translational Paper of the Year by the Journal of Immunotherapy Cancer in 2022. In addition, she is principal investigator of multicenter studies related to methotrexate-associated AKI and myeloma light chain cast nephropathy. She has gained international renown, having given invited presentations in Brazil, Peru, Switzerland, India, and China. She is on the steering committee for the ADQI consensus conference on onconephrology, and co-chair of the ICI-AKI section of the conference. In 2021, Shruti founded the American Society of Onconephrology, which now has >150 members across 14 countries, and served as the first president of the organization.

Aditi Hazra, PhD, MPH
Assistant Professor of Medicine, Division of Preventive Medicine

Moderator, Cancer Prevention and Early Detection

Dr. Hazra received her PhD in cancer biology from The University of Texas M.D. Anderson Cancer Center and was a post-doctoral fellow in the Program in Molecular and Genetic Epidemiology at the Harvard T.H. Chan School of Public Health. To identify clinically actionable biomarkers, she has led translational and collaborative research on gene regulation in cancer, including studies on germline genetic risk, nutritional genomics, cancer genomics and epigenomics. Her current research is on breast cancer genomics and her future goals are to design a strength training survivorship trial in partnership with the community. Dr. Hazra’s American Cancer Society funded research aims to evaluate the transcriptome and improve stratification of subsequent breast cancer risk among racially diverse DCIS (ductal carcinoma in situ) patients. The completion of the “precision health equity” aims may lead to personalized treatment for all DCIS patients and may prevent DCIS progression to invasive breast cancer. As a Fulbright Specialist candidate in global health, Dr. Hazra aims to improve awareness, early detection of breast cancer, and survivorship for all women.

JoAnn E Manson, MD, DrPH
Professor of Medicine, Michael and Lee Bell Professor of Women's Health

Precision Nutrition and Cancer Prevention: Lessons From Large-Scale Randomized Trials

Dr. Manson is an endocrinologist, epidemiologist, and Principal Investigator of several research studies, including the Women’s Health Initiative Clinical Center In Boston (PI since study inception in 1993); the cardiovascular component of the Nurses’ Health Study (PI for 20 years); the VITamin D and OmegA-3 TriaL (VITAL; PI with Dr. J. Buring since study inception in 2009); the COcoa Supplement and Multivitamin Outcomes Study (COSMOS, PI with Dr. H. Sesso since 2014); and others. Her primary research interests include randomized clinical prevention trials of nutritional and lifestyle factors related to heart disease, diabetes, and cancer and the role of endogenous and exogenous estrogens as determinants of chronic disease.

Dr. Manson has received numerous honors, including the American Heart Association’s (AHA) Population Research Prize, the AHA’s Distinguished Scientist Award, AHA invited lectureships (Ancel Keys and Distinguished Scientist lectures), election to the Institute of Medicine of the National Academies (National Academy of Medicine), membership in the Association of American Physicians (AAP), fellowship in AAAS, the Woman in Science Award from the American Medical Women’s Association, the Bernadine Healy Award for Visionary Leadership in Women’s Health, and the Massachusetts Medical Society awards in both Public Health and Women’s Health Research. She served as the 2011-2012 President of the North American Menopause Society. Dr. Manson has published more than 1,200 articles and is the author or editor of several books and textbooks. She was also one of the physicians featured in the National Library of Medicine’s exhibition, History of American Women Physicians.

Lydia Pace, MD, MPH
Associate Professor of Medicine, Divisions of Internal Medicine and Women's Health

Advancing early detection of breast cancer in resource-constrained settings

Dr. Lydia Pace is a primary care physician and a researcher in the Division of Women’s Health at Brigham and Women’s Hospital, and Associate Professor of Medicine at Harvard Medical School. Her research focuses on advancing equity in delivery of women’s health care services, including cancer screening, in both the United States and in limited-resource settings around the world. She is the recipient of National Cancer Institute funding to examine breast cancer care quality and implementation of early detection programs in Rwanda, where she lived from 2011-2014 and continues to work. She partners with Rwandan policymakers and with the World Health Organization’s Global Breast Cancer Initiative to develop strategies for breast cancer early detection that are integrated into primary care systems. Dr. Pace also leads policy research and clinical initiatives to improve access to high-quality contraceptive care in the United States. She directs Women’s Health Policy and Advocacy in the Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, and directs the Connors Center’s Global Women’s Health Fellowship. Clinically, she practices primary care at the Jen Center for Primary Care at Brigham and Women’s Hospital and cares for women at elevated risk of developing breast cancer in the BWH Breast Cancer Risk Assessment, Education and Prevention (B-PREP) program.

Kathryn Rexrode, MD, MPH
Professor of Medicine, Division of Women's Health

Dr. Kathryn Rexrode is the Chief Academic Officer at Brigham and Women’s Hospital (BWH), Chief of the Division of Women’s Health in the Department of Medicine at BWH, and a Professor of Medicine at Harvard Medical School.

As Chief Academic Officer she supports and advances the research and educational missions of the hospital.

Dr. Rexrode has broad and deep research experience in women’s health and is the author of more than 300 research publications. She leads multiple research studies funded by the National Institutes of Health with a focus on the impact of metabolism and female-specific risk factors on the risk of heart disease and stroke in women. She has received multiple scientific and mentorship awards and currently is Co-PI of the BIRCWH K12 training program and leads the Career Enhancement Core for the ROSA Center Specialized Center of Research in Women’s Health.

Dr. Rexrode is also the Director of the Gretchen and Edward Fish Center for Women’s Health which provides comprehensive women’s health services, including 14 specialties and a dedicated clinic for menopause and midlife care. Building on its core mission of leading the field in state-of-the-art care for women, the Division of Women’s Health conducts translational women’s health research and leads innovative education programs for medical students, residents, and faculty to advance the health of women.

* Andrea Romanos-Nanclares, PhD
Instructor in Medicine, Channing Division of Network Medicine

Planetary Health Diet Index and Breast Cancer Risk

Dr. Romanos-Nanclares is a junior faculty member, serving as an Instructor in Medicine at Harvard Medical School and an Investigator at Brigham and Women’s Hospital. She earned her Ph.D. in Biomedicine and Applied Medicine from the University of Navarra, Spain, in 2021, concentrating on nutritional and cancer epidemiology. Her research focuses on understanding the role of diet in breast cancer prevention and survival. As a recipient of the K99/R00 grant from the National Cancer Institute, Dr. Romanos-Nanclares is leading a project to investigate the role of chronic inflammation—specifically related to diet—in breast cancer development, with a particular focus on estrogen receptor-negative breast cancer. Using a multi-omics approach, she is combining metabolomics of pro-inflammatory dietary patterns, plasma proteomics, and tumor tissue transcriptomics, drawing on the extensive resources of the Nurses’ Health Studies. Her long-term goal is to integrate diet and lifestyle factors with multi-omics biomarkers to understand the biological pathways underlying aggressive breast tumors and extend this work into cancer survivorship. Through this, Dr. Romanos-Nanclares aims to advance the emerging field of precision nutrition, not only for cancer prevention but also to improve the quality of life and long-term health outcomes for cancer survivors.

Sandro Santagata, MD, PhD
Associate Professor of Pathology

New Approaches for Multiplexed Tissue Imaging of Cancer

Sandro is an Associate Professor in the Department of Pathology at Brigham and Women’s Hospital, at Harvard Medical School. He practices neuropathology with a focus on diagnosing and characterizing adult and pediatric brain tumors. He is a member of the Ludwig Center at Harvard, the Harvard Program in Therapeutic Science, and the HMS Laboratory of Systems Pharmacology. His research laboratory develops and implements methodologies to image tissues resected from cancer patients, extracting molecular information that sheds light on how cancers form and then develop their most aggressive features. With these tools, his group explores the biological properties of cancer tissues, the molecular systems tumor cells use to evade immune surveillance, and the ways that cancer and immune cells assemble into dynamic ecosystems. This rich imaging data is being made available in the form of interactive tumor atlases as part of the National Cancer Institute’s Human Tumor Atlas Network (HTAN), a consortium which is assembling 2D and 3D maps of human precancers and cancers which can be browsed and analyzed by users in research and clinical practice to advance our understanding of cancer and to find new treatments.

Jacqueline Slavik, PhD, MMSc
Executive Director, Brigham Research Institute

Dr. Jacqueline Slavik shapes and implements the BRI’s overarching mission to accelerate discoveries that improve human health by fostering groundbreaking, interdepartmental, and interdisciplinary research, ranging from basic fundamental studies to clinical innovations. She manages a small team who works to provide a clear voice for the entire BWH research community, raise the profile of research at BWH, develop mission-centric collaborations with external entities and engage the scientific community in fundraising.

Clare Tempany, MB, BCh, BAO
Ferenc Jolesz, MD Professor of Radiology

Transforming Cancer Care: NCIGT’s Trailblazing Journey in image-guided therapy for prostate cancer

Clare Tempany MB BAO BCh is the Ferenc Jolesz Professor of Radiology at Harvard Medical School, and Vice Chair of Radiology research in Department of Radiology at Brigham & Women’s Hospital, Principal investigator of the NIH funded advanced technologies for the National center for Image Guided Therapy (AT-NCIGT) and medical director of the Brigham’s Advanced Multimodality Image Guided Operating (AMIGO) Suite. An expert in prostate MRI, Tempany leads a long-standing NIH funded laboratory in Prostate cancer research encompassing MR imaging, image-guided interventions and multiple clinical trials. She and her colleagues introduced MR guided prostate biopsy and therapy in early 1990’s both now integral to prostate cancer diagnosis today.

Trey Toombs, PhD
Program Director, Brigham Research Institute

Dr. James (Trey) Toombs is the Program Director for the Brigham Research Institute (BRI) where he implements the activities of the research centers and programs sponsored by the BRI. In this role, Trey works closely with faculty leaders to develop and execute initiatives to foster new interdisciplinary and interdepartmental research programs and raise the visibility of the world-class science being conducted at the Brigham. Prior to joining the BRI, Trey received his PhD in Biochemistry and Molecular Biology from Colorado State University and was a research fellow at Harvard Medical School and Massachusetts General Hospital.

Humsa Venkatesh, PhD
Assistant Professor of Neurology

The Neural Regulation of Cancer

Humsa Venkatesh, PhD, is an Assistant Professor of Neurology at the Harvard Medical School and an Associate Scientist in Neurology at Brigham and Women's Hospital. Humsa received her undergraduate degree in Chemical Biology from the University of California, Berkeley and her PhD in Cancer Biology from Stanford University. After completing her postdoctoral work, she joined the Stanford faculty in 2019 and is now starting her Cancer Neuroscience research program as Assistant Professor at the Brigham and Women’s Hospital and Harvard Medical School. She has been recognized by the MIT Technology Review as a Pioneer Under 35 ‘TR35’ (2018), by Genetic Engineering News as a ‘Top 10 innovator to watch under 40’ (2019), and won the Science & SciLife Prize for Young Scientists (2019).

* Speakers marked with an asterisk (*) are featured speakers who were chosen from submitted abstracts to orally present short talks on their work.

Poster Award Winners

These four posters were chosen from a review of all submissions to receive a Poster Award. Check them out during the second round of posters, 3:30 – 4:00 PM!

1. Kevin Ma, MD

Sodium-glucose Cotransporter-2 Inhibitors For Type 2 Diabetes Mellitus And Lower Risk of Gastrointestinal Cancers

8. Naiara Perurena, PhD

EZH2 inhibitors dramatically sensitize breast cancers to HER2 kinase inhibitors through cooperative effects on YAP and pro-apoptotic regulators

Poster Session Round 1

2:50PM - 3:20PM

2. Annabella Boardman, BA

A Peer Support Intervention in Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation (HSCT): The STEPP Proof-of-Concept Trial

3. Chang Dai, MD, PhD

Induction Chemotherapy-Related Covert Cardiac Remodeling in Pre-Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: a Retrospective Observational Study

4. Bidisha Das, MPH

Impact of neoadjuvant radiation therapy on postoperative margin status, local recurrence, and local recurrence free survival among patients with pancreatic ductal adenocarcinoma at a high-volume cancer center

6. Moumen Elmelegy, PhD

Does the Combination of Clinical Biomarkers, Risk Factors, and Patient’s Symptoms Improve Prostate Cancer Risk Prediction?

8. Hannah Farnsworth, BS

Beyond the Local Tumor Microenvironment: Characterizing Changes to Neuronal Activity Induced by Pediatric High-Grade Glioma

9. Fu Gui, PhD

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer

11. Michelle Hess, PhD

Eliciting anti-tumor immunity in glioblastoma with a bioengineered neoantigen vaccine and nectin family checkpoint blockade therapy

12. Emma Keane, BA

Immunosuppressant Adherence in Patients with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

13. Inga Krause

Differentiation of pseudoprogression and true progression in IDH-wildtype glioblastomas using amide proton transfer weighted (APTw) imaging at 3 Tesla

14. Isabella Larizza, BS

The Peer Mentor Perspective on a Peer Support Intervention (STEPP) for Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

16. John Lian, BS

Determining the Association Between Tumor Mutational Burden and Host Immune Response Using Natural Language Processing

19. Jing Luo, PhD

Targeting Mitochondrial Complex I to enhance PARP inhibition Efficacy in Prostate Cancer Therapy

Poster Session Round 2

3:30PM - 4:00PM

1. Kevin Ma, MD

Sodium-glucose Cotransporter-2 Inhibitors For Type 2 Diabetes Mellitus And Lower Risk of Gastrointestinal Cancers

4. Pravee Meka, MD

Interpreting Blood Gases using Anthropic Claude v3, a large language model with a decision architecture

5. Bidisha Mitra, PhD

Characterization of the roles of the two Epstein-Barr virus oncogene LMP1 domains essential for B-cell transformation

8. Naiara Perurena, PhD

EZH2 inhibitors dramatically sensitize breast cancers to HER2 kinase inhibitors through cooperative effects on YAP and pro-apoptotic regulators

9. Abolfazl Salari, MD

Association of hospital quality, county-level social vulnerability index, and zip-code level community distress index with short-term surgical outcomes among Medicare beneficiaries undergoing elective cancer surgery

10. Samer Salem, MD

Ferroptosis Suppressor Protein 1 (FSP1) is a Potent and Targetable Inhibitor of Ferroptosis in Chromophobe Renal Cell Carcinoma

11. Jian Zhao, PhD

Using network analysis to understand pain, psychological symptoms, and sleep disturbance during acute pain exacerbations among groups of cancer patients presenting to ED with pain: The impact of recent surgery

18. Dandan Yang, PhD

Glucocorticoid receptor signaling regulates metabolic rewiring to shape the effector differentiation of CD8+ tumor-infiltrating T cells

19. Dongyi Zhao, PhD

The role of DNA damage in the acquisition of the stem cell-like program in breast cancer initiation, risk, or susceptibility

Room Directions

Marshall A. Wolf Conference Center

3rd floor, Hale Building for Transformative Medicine (Hale BTM):

From 60 Fenwood Road: Enter at 60 Fenwood Rd lobby entrance.

STAIRS:

Take the lobby staircase to the 2nd floor. Walk past the balcony overlooking the atrium and take the stairs on the left (Stair 2) to the 3rd floor. Once on the 3rd floor, exit the stairwell and take a right. The room is to your right through the double glass door, straight ahead.

ELEVATOR:

Take S Elevator to 3rd floor. Take a right out of the elevator. The room is past the stairwell, on your right through the double glass doors.

 

Satter Atrium (previously called Hale Cafe Atrium)

1st floor, Hale Building for Transformative Medicine (Hale BTM):

From 60 Fenwood Road: Coming from Marshall A. Wolf Conference Center.

STAIRS

Coming from Marshall A. Wolf Conference Center, exit through the double glass doors and take the stairwell, which is located on the left, to the 1st Floor, and the Satter Atrium is located in the open space to your right.

ELEVATOR:

Take the S elevators (or employee elevators if you have access) to the 1st floor, and the atrium will be on your right.